Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017, outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Papillomavirus Minor Capsid Protein L2 (L2) - L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dyne in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins. The molecules developed by companies in Preclinical stages are 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Cervical Cancer, Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Genital Warts (Condylomata Acuminata) and Warts.

Furthermore, this report also reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Topics Covered:

1. Introduction
2. Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview
3. Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development
4. Products under Development by Stage of Development
5. Products under Development by Therapy Area
6. Products under Development by Indication
7. Products under Development by Companies
8. Products under Development by Universities/Institutes
9. Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment
10. Assessment by Route of Administration
11. Assessment by Molecule Type
12. Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in Therapeutics Development

• Agilvax Inc
• Cancer Research Technology Ltd
• Pathovax LLC

For more information about this report visit https://www.researchandmarkets.com/research/v29gcq/human